|
1
|
Antidepressant drug effects and depression severity: a patient-level meta-analysis.
|
JAMA
|
2010
|
13.88
|
|
2
|
Cognitive therapy vs medications in the treatment of moderate to severe depression.
|
Arch Gen Psychiatry
|
2005
|
5.72
|
|
3
|
L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials.
|
Am J Psychiatry
|
2012
|
3.73
|
|
4
|
Prevention of relapse following cognitive therapy vs medications in moderate to severe depression.
|
Arch Gen Psychiatry
|
2005
|
3.46
|
|
5
|
Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.
|
Am J Psychiatry
|
2011
|
3.34
|
|
6
|
MDDScore: confirmation of a blood test to aid in the diagnosis of major depressive disorder.
|
J Clin Psychiatry
|
2015
|
2.66
|
|
7
|
Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies.
|
Am J Obstet Gynecol
|
2012
|
2.16
|
|
8
|
Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis.
|
J Clin Psychiatry
|
2007
|
2.10
|
|
9
|
Signal transduction abnormalities in melancholic depression.
|
Int J Neuropsychopharmacol
|
2004
|
1.73
|
|
10
|
Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
|
Biol Psychiatry
|
2007
|
1.68
|
|
11
|
Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression.
|
J Consult Clin Psychol
|
2009
|
1.67
|
|
12
|
Effort-based decision-making in major depressive disorder: a translational model of motivational anhedonia.
|
J Abnorm Psychol
|
2012
|
1.63
|
|
13
|
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
|
J Clin Psychiatry
|
2007
|
1.54
|
|
14
|
Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer.
|
Oncologist
|
2007
|
1.54
|
|
15
|
Human serotonin transporter variants display altered sensitivity to protein kinase G and p38 mitogen-activated protein kinase.
|
Proc Natl Acad Sci U S A
|
2005
|
1.53
|
|
16
|
Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features.
|
J Affect Disord
|
2005
|
1.49
|
|
17
|
Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies.
|
J Clin Psychopharmacol
|
2006
|
1.47
|
|
18
|
Agomelatine for the treatment of major depressive disorder.
|
Expert Opin Pharmacother
|
2011
|
1.45
|
|
19
|
Antidepressant medications v. cognitive therapy in people with depression with or without personality disorder.
|
Br J Psychiatry
|
2008
|
1.44
|
|
20
|
Functional biomarkers of depression: diagnosis, treatment, and pathophysiology.
|
Neuropsychopharmacology
|
2011
|
1.44
|
|
21
|
The current crisis of confidence in antidepressants.
|
J Clin Psychiatry
|
2011
|
1.44
|
|
22
|
Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder.
|
J Clin Psychiatry
|
2016
|
1.43
|
|
23
|
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study.
|
J Clin Psychiatry
|
2007
|
1.40
|
|
24
|
Review of pharmacological treatment in mood disorders and future directions for drug development.
|
Neuropsychopharmacology
|
2011
|
1.28
|
|
25
|
Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine.
|
J Psychiatr Res
|
2008
|
1.26
|
|
26
|
Early- and late-onset startle modulation in unipolar depression.
|
Psychophysiology
|
2004
|
1.20
|
|
27
|
Sustained amygdala response to both novel and newly familiar faces characterizes inhibited temperament.
|
Soc Cogn Affect Neurosci
|
2010
|
1.17
|
|
28
|
The relation of patients' treatment preferences to outcome in a randomized clinical trial.
|
Behav Ther
|
2007
|
1.10
|
|
29
|
Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression.
|
J Consult Clin Psychol
|
2007
|
1.08
|
|
30
|
Two aspects of the therapeutic alliance: differential relations with depressive symptom change.
|
J Consult Clin Psychol
|
2011
|
1.08
|
|
31
|
A randomized, double-blind, crossover trial of modafinil on mood.
|
J Clin Psychopharmacol
|
2007
|
1.08
|
|
32
|
Amygdala temporal dynamics: temperamental differences in the timing of amygdala response to familiar and novel faces.
|
BMC Neurosci
|
2009
|
1.06
|
|
33
|
Early adverse events, HPA activity and rostral anterior cingulate volume in MDD.
|
PLoS One
|
2009
|
1.06
|
|
34
|
Depressive realism and clinical depression.
|
Behav Res Ther
|
2009
|
1.05
|
|
35
|
Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression.
|
Biol Psychiatry
|
2006
|
1.05
|
|
36
|
Presenting characteristics of depressed outpatients as a function of recurrence: preliminary findings from the STAR*D clinical trial.
|
J Psychiatr Res
|
2005
|
1.04
|
|
37
|
Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder.
|
Neuropharmacology
|
2005
|
1.04
|
|
38
|
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.
|
Biol Psychiatry
|
2007
|
0.99
|
|
39
|
Identifying suicidal behavior among adolescents using administrative claims data.
|
Pharmacoepidemiol Drug Saf
|
2013
|
0.98
|
|
40
|
Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research.
|
J Clin Psychiatry
|
2006
|
0.96
|
|
41
|
Predictors of patient cognitive therapy skills and symptom change in two randomized clinical trials: the role of therapist adherence and the therapeutic alliance.
|
J Consult Clin Psychol
|
2012
|
0.94
|
|
42
|
The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies.
|
J Clin Psychiatry
|
2008
|
0.92
|
|
43
|
Assessing the effects of bupropion SR on mood dimensions of depression.
|
J Affect Disord
|
2004
|
0.92
|
|
44
|
Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort.
|
J Clin Psychiatry
|
2007
|
0.91
|
|
45
|
Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development.
|
Aust N Z J Psychiatry
|
2012
|
0.90
|
|
46
|
Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder.
|
J Affect Disord
|
2013
|
0.90
|
|
47
|
Crisis of confidence: antidepressant risk versus benefit.
|
J Clin Psychiatry
|
2011
|
0.89
|
|
48
|
Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study.
|
J Clin Psychiatry
|
2007
|
0.89
|
|
49
|
Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy.
|
J Affect Disord
|
2008
|
0.87
|
|
50
|
Oxidative stress and glutathione response in tissue cultures from persons with major depression.
|
J Psychiatr Res
|
2012
|
0.86
|
|
51
|
A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
|
J Clin Psychiatry
|
2011
|
0.86
|
|
52
|
Decreased serotonin 5-HT2A receptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients.
|
Neuropsychopharmacology
|
2004
|
0.85
|
|
53
|
Increasing use of atypical antipsychotics and anticonvulsants during pregnancy.
|
Pharmacoepidemiol Drug Saf
|
2012
|
0.84
|
|
54
|
Depression in patients with head and neck cancer and a functional genetic polymorphism of the serotonin transporter gene.
|
Head Neck
|
2011
|
0.84
|
|
55
|
Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE): a pragmatic trial of complex treatment for a complex disorder.
|
Clin Trials
|
2013
|
0.84
|
|
56
|
Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder.
|
Expert Rev Neurother
|
2010
|
0.84
|
|
57
|
Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release.
|
J Affect Disord
|
2010
|
0.84
|
|
58
|
Do venlafaxine XR and paroxetine equally influence negative and positive affect?
|
J Affect Disord
|
2005
|
0.83
|
|
59
|
Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy.
|
Behav Res Ther
|
2013
|
0.83
|
|
60
|
Long-term efficacy, safety, and tolerability of L-methylfolate calcium 15 mg as adjunctive therapy with selective serotonin reuptake inhibitors: a 12-month, open-label study following a placebo-controlled acute study.
|
J Clin Psychiatry
|
2016
|
0.82
|
|
61
|
Use of atypical antipsychotics for treatment-resistant major depressive disorder.
|
Curr Psychiatry Rep
|
2008
|
0.82
|
|
62
|
Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial.
|
J Clin Psychiatry
|
2014
|
0.82
|
|
63
|
Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.
|
Neuropsychiatr Dis Treat
|
2009
|
0.81
|
|
64
|
Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE).
|
Bipolar Disord
|
2014
|
0.80
|
|
65
|
Converting from brand-name to generic clozapine: a review of effectiveness and tolerability data.
|
Am J Health Syst Pharm
|
2010
|
0.79
|
|
66
|
Antidepressants and suicide attempts in children.
|
Pediatrics
|
2014
|
0.79
|
|
67
|
Use of treatment algorithms for depression.
|
J Clin Psychiatry
|
2006
|
0.79
|
|
68
|
Treatment resistant depression: strategies for primary care.
|
Curr Psychiatry Rep
|
2013
|
0.78
|
|
69
|
A randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder.
|
Clin Neuropharmacol
|
2011
|
0.78
|
|
70
|
Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.
|
Expert Rev Neurother
|
2010
|
0.77
|
|
71
|
A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.
|
J Clin Psychiatry
|
2012
|
0.77
|
|
72
|
Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial.
|
Hum Psychopharmacol
|
2010
|
0.77
|
|
73
|
Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
|
J Affect Disord
|
2011
|
0.77
|
|
74
|
Convergence and divergence in the delivery of cognitive therapy in two randomized clinical trials.
|
Behav Res Ther
|
2013
|
0.77
|
|
75
|
The effect of regulatory advisories on maternal antidepressant prescribing, 1995-2007: an interrupted time series study of 228,876 pregnancies.
|
Arch Womens Ment Health
|
2013
|
0.77
|
|
76
|
Complexity of illness and adjunctive benzodiazepine use in outpatients with bipolar I or II disorder: results from the Bipolar CHOICE study.
|
J Clin Psychopharmacol
|
2015
|
0.77
|
|
77
|
Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.
|
Expert Opin Pharmacother
|
2009
|
0.76
|
|
78
|
Use of treatment algorithms for depression.
|
Prim Care Companion J Clin Psychiatry
|
2006
|
0.76
|
|
79
|
Ziprasidone augmentation for anxious depression.
|
Int Clin Psychopharmacol
|
2016
|
0.76
|
|
80
|
Effects of orally disintegrating vs regular olanzapine tablets on body weight, eating behavior, glycemic and lipid indices, and gastrointestinal hormones: a randomized, open comparison in outpatients with bipolar depression.
|
Ann Clin Psychiatry
|
2011
|
0.76
|
|
81
|
Bipolar depression: best practices for the outpatient.
|
CNS Spectr
|
2007
|
0.76
|
|
82
|
BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
|
Prog Neuropsychopharmacol Biol Psychiatry
|
2013
|
0.75
|
|
83
|
Reply to commentary by Rothschild: "A Blood Test for Depression?".
|
J Clin Psychiatry
|
2015
|
0.75
|
|
84
|
Evidence for the use of l-methylfolate combined with antidepressants in MDD.
|
J Clin Psychiatry
|
2011
|
0.75
|
|
85
|
The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication.
|
J Clin Psychiatry
|
2004
|
0.75
|
|
86
|
Does concomitant use of NSAIDs reduce the effectiveness of antidepressants?
|
Am J Psychiatry
|
2012
|
0.75
|
|
87
|
Detection of an mRNA polymorphism by differential display.
|
Methods Mol Biol
|
2006
|
0.75
|
|
88
|
Baseline disability and poor functioning in bipolar disorder predict worse outcomes: results from the Bipolar CHOICE study.
|
J Clin Psychiatry
|
2016
|
0.75
|